Latest News for: eortc

Edit

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual ...

Nasdaq Globe Newswire 20 Oct 2021
... models supporting the use of plinabulin in small cell lung cancer (SCLC) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.
Edit

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer (BeyondSpring Inc)

Public Technologies 20 Oct 2021
BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the presentation of preclinical data in patient-derived (PDX) cancer models supporting the use of plinabulin in small cell lung cancer (SCLC) at the 2021 AACR-NCI-EORTC ...
Edit

Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Nasdaq Globe Newswire 12 Oct 2021
Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors. Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors ... .
Edit

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International ...

The Associated Press 11 Oct 2021
... three key preclinical datasets highlighting the potential of its lead product candidate, IMM-1-104, were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that took place virtually from October 7-10, 2021.ADVERTISEMENT.
Edit

Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly ...

Nasdaq Globe Newswire 08 Oct 2021
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor ... .
Edit

AACR-NCI-EORTC Molecular Targets and Cancer Therapuetics Conference Presentation (Oncternal Therapeutics Inc)

Public Technologies 08 Oct 2021
). ONCT-534, an Androgen Receptor (AR) N-Terminal-Domain-Binding Small Molecule Degrader, for the Treatment of AR-Variant 7 (AR-V7)-Positive Castration- Resistant Prostate Cancer. Ramesh Narayanan, Ph.D., MBA,. Professor, University of Tennessee Health Science Center,. Memphis, TN, USA. Disclosure ... James B. Breitmeyer & Gunnar F ... Objective ... of ONCT-534.
Edit

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Black Diamond Therapeutics Inc)

Public Technologies 08 Oct 2021
BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of preclinical data for three early-stage pipeline programs in oral and poster sessions at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Edit

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Repare Therapeutics Inc)

Public Technologies 08 Oct 2021
The data are featured today at the AACR-NCI-EORTC conference in an oral presentation titled, "First-in-Human biomarker-driven Phase I TRESR trial of ATR inhibitor RP-3500 in patients with advanced solid tumors harboring synthetic lethal genomic alterations" (Abstract number 4950).
×